Clinical trials: Sorafenib
Breast Cancer
Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Breast Cancer Patients
Endocrine therapy is the mainstay of systemic treatment in patients with endocrine responsive breast cancer. Aromatase inhibitors are the most active agents in post-menopausal women.
- Trial name
- NCT00954135
- Testing
- letrozolo+cyclophosphamide, letrozolo+sorafenib+cyclophosphamide
- Where
- 2 sites in Italy
- Volunteers
- 190 people
- Sponsor
- University of Turin, Italy
Advanced Cancer
Bevacizumab in Multiple Phase I Combinations
The goal of this clinical research study is to find the highest tolerable dose of Avastin™ that can be given in combination with 4 other study drug/drug combinations.
- Trial name
- NCT00543504
- Testing
- Bevacizumab, Sorafenib, Erlotinib
- Where
- United States
- Volunteers
- 343 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Cancer
Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
The purpose of this study is to evaluate the efficacy and tolerability of sorafenib as second line treatment in patients with Advanced or Metastatic Gastric Cancer (A/MGC).
- Trial name
- NCT00595985
- Testing
- sorafenib
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
This is a Phase I study, which means that the goal is to see if the combination of Temsirolimus and Sorafenib is safe in patients with Hepatocellular Carcinoma. Sorafenib is a standard treatment for Hepatocellular Carcinoma.
- Trial name
- NCT01008917
- Testing
- sorafenib with temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute
Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
The purpose of this study is to test the safety of sorafenib and vorinostat when given together to see what effects (good and bad) it has on the patient and their acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Myelodysplastic Syndromes
- Trial name
- NCT00875745
- Testing
- Sorafenib-Vorinostat
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Indiana University
Breast Cancer
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
The objective of this phase-III trial is to compare the efficacy and safety of sorafenib in combination with capecitabine versus capecitabine in combination with placebo in the treatment of subjects with locally advanced or…
- Trial name
- NCT01234337
- Testing
- Sorafenib (Nexavar, BAY43-9006), Capecitabine
- Where
- 153 sites in United States, Argentina and 21 more
- Volunteers
- 537 people
- Sponsor
- Bayer
Metastatic Colorectal Cancer
Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer
The purpose of this study is to assess the safety, the maximum tolerated dose and the recommended dose for phase II studies of a chemotherapy-combination of sorafenib, irinotecan, and 5-fluorouracil (5-FU)/folinic acid (FA)…
- Trial name
- NCT00780169
- Testing
- sorafenib + FOLFIRI
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Ottawa Hospital Research Institute
Acute Myeloid Leukemia
Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML
The primary purpose of the study is to determine, whether the addition of Sorafenib to standard chemotherapy in elderly patients with newly diagnosed AML improves treatment results (event free survival).
- Trial name
- NCT00373373
- Testing
- Sorafenib
- Where
- 18 sites in Germany
- Volunteers
- 200 people
- Sponsor
- University Hospital Muenster
Carcinoma, Renal Cell
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
The purpose of this study is to evaluate safety, efficacy (including quality of life), and pharmacokinetics of BAY43-9006 when added to Best Supportive Care in patients with unresectable and/or metastatic renal cell cancer, who…
- Trial name
- NCT00073307
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 121 sites in United States, Argentina and 17 more
- Volunteers
- 903 people
- Sponsor
- Bayer
Liver Cancer
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
The purpose of this study is to evaluate the effect of combining a new investigational drug (OSI-906) with a standard drug (sorafenib) on the control of liver cancer (hepatocellular cancer).
- Trial name
- NCT01334710
- Testing
- Sorafenib and OSI-906
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Emory University
Neoplastic Meningitis
Depocyt® With Sorafenib in Neoplastic Meningitis
The purpose of this study is to determine the tolerability and side effects of oral sorafenib in combination with intrathecal DepoCyt.
- Trial name
- NCT00964743
- Testing
- DepoCyt, Sorafenib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma (Skin)
Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00565968
- Testing
- melphalan, sorafenib tosylate, gene expression analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
This phase II trial is studying how well giving sorafenib with interferon alfa works in treating patients with metastatic or unresectable kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00101114
- Testing
- sorafenib tosylate, recombinant interferon alfa-2b, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Thyroid Cancer, Insular Thyroid Cancer
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
Phase II trial to study the effectiveness of sorafenib tosylate in treating patients who have locally advanced, metastatic, or locally recurrent thyroid cancer.
- Conditions
- Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage III Follicular Thyroid Cancer
- Trial name
- NCT00095693
- Testing
- sorafenib tosylate, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocyte Receptor, Hepatocellular Carcinoma
Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in Resistance to Treatment With Sorafenib in CHC Patients
Primary liver cancer or hepatocellular carcinoma (HCC) is the 7th most common cancer in humans; 9th in women (figures from the Association for Research against Cancer ARC).
- Trial name
- SLAMF3 (NCT03113604)
- Testing
- Study on samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma
- Where
- France
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Hepatocellular Carcinoma, Recurrence
Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
This prospective multicenter non-randomized controlled study evaluates the efficacy and safety of treatment with Sorafenib (Nevaxar) in patients with hepatocellular carcinoma with microvascular invasion after radical resection…
- Trial name
- NCT02867280
- Testing
- Sorafenib
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Sun Yat-sen University
Advanced Gastric Cancer
Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP
There is strong scientific rationale for exploring the role of sorafenib with capecitabine and cisplatin (XP) in AGC. XP is a new standard of care in AGC and sorafenib is a novel signal transduction inhibitor that prevents tumor…
- Trial name
- NCT00565370
- Testing
- Capecitabine, Cisplatin, Sorafenib
- Where
- South Korea
- Volunteers
- 22 people
- Sponsor
- Asan Medical Center
Acute Myeloid Leukemia
Sorafenib In Relapse of FMS-like Tyrosine Kinase 3 (FLT3)-Internal Tandem Duplication (ITD) AML Trial
In this trial the investigators will evaluate the outcomes of 4 pre-defined groups of individuals according to the therapeutic intervention.
- Trial name
- SIRA (NCT02867891)
- Volunteers
- 396 people
- Sponsor
- Robert Zeiser
Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
This randomized phase III trial studies sorafenib tosylate and doxorubicin hydrochloride to see how well they work compared with sorafenib tosylate alone in treating patients with liver cancer that has spread to nearby tissue or…
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7
- Trial name
- NCT01015833
- Testing
- Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacogenomic Study
- Where
- 673 sites in United States, Canada and 1 more
- Volunteers
- 356 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Differentiated Thyroid Cancer, Metastatic Poorly Differentiated Thyroid Cancer
Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
The goal of this study is to determine the activity of sorafenib in patients with advanced (metastatic or recurrent) thyroid cancer.
- Conditions
- Metastatic Differentiated Thyroid Cancer, Metastatic Poorly Differentiated Thyroid Cancer, Metastatic Anaplastic Thyroid Cancer, Metastatic Medullary Thyroid Cancer
- Trial name
- NCT00654238
- Testing
- sorafenib
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- University of Pennsylvania